Researchers introduced a new mRNA cancer vaccine that rapidly activates the immune system against glioblastoma, the deadliest form of brain tumor. This new vaccine technology, which mimics the structure of COVID-19 vaccines but incorporates personalized tumor cells and a complex cluster delivery system, has shown promising results in preclinical models and an initial human trial involving four adult patients.
